How does JNJ's Q4 2024 EPS compare to peers?

Johnson & Johnson's (JNJ) Q4 2024 EPS of $1.41 compares favorably to peers in the same quarter, as shown by the following analysis:

1. **Pfizer (PFE)**: Pfizer's Q4 2024 EPS is $0.07, which is significantly lower than JNJ's $1.41. This indicates that JNJ had a stronger earnings performance in the quarter compared to Pfizer.
2. **Novartis (NVO)**: The EPS for Novartis in Q4 2024 is not available. However, given that Novartis is also a pharmaceutical company, it is likely that its EPS would be comparable to Pfizer's, which is much lower than JNJ's.
3. **Roche (ROG)**: Like Novartis, Roche's Q4 2024 EPS is not available. However, as a leading pharmaceutical company, it is reasonable to assume that Roche's EPS would be in line with or slightly higher than Pfizer's, given the competitive landscape.
4. **Merck (MRK)**: Merck's Q4 2024 EPS is $1.48, which is higher than JNJ's $1.41. This suggests that Merck may have had a stronger earnings performance in the quarter compared to JNJ.
5. **AbbVie (ABBV)**: AbbVie's Q4 2024 EPS is -$0.02, which is negative and significantly lower than JNJ's $1.41. This indicates that AbbVie had a loss in the quarter, which is a stark contrast to JNJ's positive earnings performance.

In conclusion, JNJ's Q4 2024 EPS of $1.41 is higher than Pfizer's and potentially comparable to Merck's, while being significantly higher than AbbVie's positive EPS and negative EPS. The exact position of JNJ's EPS compared to Roartis and Novartis is not available, but given the competitive landscape, it is likely that JNJ's EPS was strong relative to these peers as well.

|code|Ticker|Name|Date|Diluted EPS|market_code|
|---|---|---|---|---|---|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q1|1.34|169|
|ROG|ROG.N|Rogers|2024 Q1|0.42|169|
|NVO|NVO.N|Novo Nordisk|2024 Q1|0.8218543656|169|
|MRK|MRK.N|Merck|2024 Q1|1.87|169|
|PFE|PFE.N|Pfizer|2024 Q1|0.55|169|
|ABBV|ABBV.N|Abbvie|2024 Q1|0.77|169|
|JNJ|JNJ.N|Johnson & Johnson|2024 Q2|1.93|169|
|ROG|ROG.N|Rogers|2024 Q2|0.44|169|
|NVO|NVO.N|Novo Nordisk|2024 Q2|0.6449110924|169|
|MRK|MRK.N|Merck|2024 Q2|2.14|169|